Equities research analysts predict that Las Vegas Sands Corp. (NYSE:LVS) will report $3.31 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Las Vegas Sands’ earnings, with the highest sales estimate coming in at $3.37 billion and the lowest estimate coming in at $3.26 billion. Las Vegas Sands reported sales of $3.37 billion during the same quarter last year, which would suggest a negative year-over-year growth rate of 1.8%. The business is expected to issue its next earnings results on Wednesday, October 23rd.
According to Zacks, analysts expect that Las Vegas Sands will report full year sales of $13.74 billion for the current year, with estimates ranging from $13.68 billion to $13.86 billion. For the next fiscal year, analysts forecast that the business will post sales of $13.91 billion, with estimates ranging from $13.75 billion to $14.03 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Las Vegas Sands.
Las Vegas Sands (NYSE:LVS) last released its earnings results on Wednesday, July 24th. The casino operator reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.09). The firm had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.39 billion. Las Vegas Sands had a return on equity of 35.77% and a net margin of 14.01%. The company’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.76 EPS.
A number of equities research analysts have recently weighed in on LVS shares. Argus downgraded Las Vegas Sands from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th. Morgan Stanley dropped their price objective on Las Vegas Sands from $68.00 to $66.00 and set an “overweight” rating for the company in a report on Tuesday, September 17th. Deutsche Bank upgraded Las Vegas Sands from a “hold” rating to a “buy” rating and upped their price objective for the company from $69.00 to $70.00 in a report on Sunday, September 8th. Standpoint Research assumed coverage on Las Vegas Sands in a report on Wednesday, September 4th. They issued a “buy” rating for the company. Finally, JPMorgan Chase & Co. dropped their price objective on Las Vegas Sands from $68.00 to $60.00 and set a “neutral” rating for the company in a report on Friday, September 6th. Ten research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Las Vegas Sands has a consensus rating of “Hold” and an average price target of $67.23.
In other Las Vegas Sands news, General Counsel Kathleen Bender Patton sold 2,008 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $35.60, for a total value of $71,484.80. Also, EVP Lawrence A. Jacobs sold 66,667 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $60.16, for a total value of $4,010,686.72. Following the completion of the transaction, the executive vice president now directly owns 66,667 shares of the company’s stock, valued at $4,010,686.72. The disclosure for this sale can be found here. Corporate insiders own 10.50% of the company’s stock.
Large investors have recently bought and sold shares of the business. Manchester Financial Inc. acquired a new position in Las Vegas Sands in the second quarter valued at about $26,000. Manchester Capital Management LLC grew its stake in Las Vegas Sands by 164.8% in the second quarter. Manchester Capital Management LLC now owns 482 shares of the casino operator’s stock valued at $28,000 after acquiring an additional 300 shares during the period. Lenox Wealth Advisors LLC grew its stake in Las Vegas Sands by 247.1% in the third quarter. Lenox Wealth Advisors LLC now owns 486 shares of the casino operator’s stock valued at $28,000 after acquiring an additional 346 shares during the period. Allworth Financial LP grew its stake in Las Vegas Sands by 195.6% in the third quarter. Allworth Financial LP now owns 538 shares of the casino operator’s stock valued at $31,000 after acquiring an additional 356 shares during the period. Finally, Rehmann Capital Advisory Group grew its stake in Las Vegas Sands by 49.0% in the first quarter. Rehmann Capital Advisory Group now owns 605 shares of the casino operator’s stock valued at $37,000 after acquiring an additional 199 shares during the period. 36.30% of the stock is owned by hedge funds and other institutional investors.
Shares of LVS stock traded up $0.41 on Friday, reaching $54.58. 237,415 shares of the stock were exchanged, compared to its average volume of 8,211,999. The stock has a market cap of $42.30 billion, a PE ratio of 16.45, a P/E/G ratio of 7.23 and a beta of 1.60. Las Vegas Sands has a one year low of $47.39 and a one year high of $69.60. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.64 and a quick ratio of 1.62. The stock has a 50 day moving average price of $56.22 and a 200 day moving average price of $59.87.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 26th. Investors of record on Wednesday, September 18th were issued a $0.77 dividend. The ex-dividend date of this dividend was Tuesday, September 17th. This represents a $3.08 dividend on an annualized basis and a yield of 5.64%. Las Vegas Sands’s dividend payout ratio is presently 92.77%.
Las Vegas Sands Company Profile
Las Vegas Sands Corp., together with its subsidiaries, develops, owns, and operates integrated resorts in Asia and the United States. It owns and operates The Venetian Macao Resort Hotel, the Sands Cotai Central, The Parisian Macao, The Plaza Macao and Four Seasons Hotel Macao, Cotai Strip, and the Sands Macao in Macao, the People's Republic of China; and iconic Marina Bay Sands in Singapore.
Read More: Earnings Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com